University of Colorado Cancer Center Support Grant

项目总结/摘要 科罗拉多大学癌症中心（UCCC），在其29年的NCI指定，已建立在其“优秀” 2011年的总体评级，具有重大科学进步和国家领导地位。服务于 科罗拉多州，UCCC，医学院内的矩阵，是一个多学科的研究财团， 位于丹佛和博尔德的科罗拉多大学，科罗拉多州立大学和临床附属大学 科罗拉多医院，儿童医院科罗拉多和丹佛弗吉尼亚州。UCCC实现了它的使命， 通过跨学科的合作研究，发展和实现癌症科学的突破。UCCC 具有改变癌症医学潜力的发现包括：1）考克斯-2在驱动原位癌进展中的作用， 乳腺癌的预防试验正在开发中; 2）放射性粘膜炎的分子基础 转化为幸存者的治疗策略; 3）Ral的“一流”抑制剂， 已知“不坚固”的GTdR可导致许多胰腺癌、结肠癌和肺癌，目前正处于商业开发阶段; 4)雄激素受体在乳腺癌中的作用，导致了DOD临床转化研究奖， 口服抗雄激素治疗三阴性癌症的国家试验; 5）显示肺癌的基因型导向治疗 癌症导致更好的生存率; 6）研究者发起的试验（IIT）中的新型治疗组合， 癌症，从合成致命的功能基因组筛选发展而来。UCCC的国家领导和 认可包括我们的肺孢子，LAPS U10和ET-CTN UM 1赠款支持NCTN和CTEP试验， SPECS U 01拨款，当选NCCN，并上升到USNWR的第15个成人癌症项目。UCCC有 196名（28名新成员）正式成员，占CO所有NCI资助PI的96%，6个项目：分子肿瘤学 (MO);癌细胞生物学（CCB）;发育治疗学（DT）;血液学恶性肿瘤（HEME）;肺， 头颈癌（LHN）和癌症预防和控制（CPC）。自2011年7月以来，2 636份出版物 (22方案间和方案内产生的影响分别为1%和25%，其中15%具有高影响（>9.6 IF）（以前为13%）， 88项专利已获颁发，26项许可协议已达成（增长104%和116%），15家初创公司成立，47家 干预IIT开放。2015年，会员持有5200万美元的直接同行评审癌症资金（2015年增加了24%）。 NCI赠款数量），1499例受试者（增加52%）参与干预试验，706/3946例新登记 患者（18%）进行干预治疗试验。利用机构和NIH的10个共享资源 投资支持UCCC研究。熟练的管理，招聘，7400万美元的投资和3个新的 捐赠的椅子，解决NCI现场访问和EAB的关注。未来的方向包括多学科举措 促进健康生活，解决对靶向药物的耐药性，加强免疫治疗，利用比较 肿瘤学，扩大癌症生物工程和发展全州范围的临床研究网络。CCSG更新和 6500万美元和2万平方英尺的新的机构承诺将使UCCC保持其上升轨迹 这是一项具有高度影响力的贡献，有助于减少其集水区和全世界的癌症负担。

PROJECT SUMMARY / ABSTRACT The University of Colorado Cancer Center (UCCC), in its 29th year of NCI designation, has built on its “excellent” overall rating in 2011, with major scientific advances and national leadership. Serving the catchment area of the State of Colorado, UCCC, a matrix within the School of Medicine, is a multidisciplinary research consortium of the University of Colorado at Denver and Boulder, Colorado State University and clinical affiliates University of Colorado Hospital, Children’s Hospital Colorado and the Denver VA. The UCCC achieves its mission to discover, develop, and deliver breakthroughs in cancer science through interdisciplinary collaborative research. UCCC discoveries with potential to change cancer medicine include: 1) role of COX-2 in driving progression of in situ disease to breast carcinoma with a prevention trial being developed; 2) molecular basis of radiation mucositis translated into treatment strategies for survivors; 3) “first in class” inhibitor of Ral, a previously deemed “undrugable” GTPase known to drive many pancreatic, colon and lung cancers, now in commercial development; 4) role of androgen receptor in breast cancer, leading to a DOD Clinical Translational Research Award and national trial of oral antiandrogens in triple negative cancers; 5) showing genotype-directed therapy in lung cancer leads to better survival; 6) novel therapeutic combinations in Investigator Initiated Trials (IIT) in multiple cancers, developed from synthetic lethal functional genomic screens. The UCCC’s national leadership and recognition include our Lung SPORE, LAPS U10 and ET-CTN UM1 grants supporting NCTN and CTEP trials, a SPECS U01 grant, election into the NCCN, and rise to 15th adult cancer program in USNWR. The UCCC has 196 (28 new) Full members, representing 96% of all NCI-funded PIs in CO, in 6 programs: Molecular Oncology (MO); Cancer Cell Biology (CCB); Developmental Therapeutics (DT); Hematologic Malignancies (HEME); Lung, Head & Neck Cancer (LHN), and Cancer Prevention and Control (CPC). Since July 2011, 2,636 publications (22% inter- and 25% intra-programmatic) were produced with 15% having high (>9.6 IF) impact (13% previously), 88 patents issued, 26 licenses negotiated (104% and 116% increase), 15 startup companies founded and 47 intervention IITs opened. In 2015, members held $52M in direct peer-reviewed cancer funding (24% increase in # of NCI grants), accrued 1499 subjects (52% increase) to intervention trials and 706/3946 newly registered patients (18%) to intervention treatment trials. 10 Shared Resources that leverage institutional and NIH investments support UCCC research. Skillful management, recruitments, a $74M investment and 3 new endowed chairs, addressed NCI site visit and EAB concerns. Future directions include multidisciplinary initiatives to promote healthy living, tackle resistance to targeted agents, enhance immunotherapy, leverage comparative oncology, expand cancer bioengineering and develop a statewide clinical research network. CCSG renewal and new institutional commitments of $65M and 20K sf of space will allow the UCCC to maintain its upward trajectory of high impact contributions and help reduce the cancer burden in its catchment area and worldwide.